LENZ Therapeutics (LENZ) Q1 2026 earnings review
Slow VIZZ Revenue Ramp Despite Strong Prescription Growth
LENZ Therapeutics is proving that building a new category for presbyopia is an expensive endeavor. While VIZZ prescriptions grew 19% sequentially to 25,000 and unique prescribers surpassed 10,000, net product revenue lagged, rising only 7% to $1.7 million. At the same time, SG&A surged to $45.0 million to fund the Sarah Jessica Parker DTC campaign and a sales force expansion. The company is leaning heavily into consumer activation to drive demand, but the massive mismatch between marketing spend and early revenue highlights the execution risk ahead, even with a healthy $258.4 million cash runway.
🐂 Bull Case
Over 10,000 unique ECPs have prescribed VIZZ from launch through Q1 2026, with approximately 60% writing multiple prescriptions. This indicates strong foundational physician trust and product efficacy.
The company expanded its sales force from 88 to 117 territories and initiated a pilot network television campaign to translate consumer awareness into active patient requests.
🐻 Bear Case
Q1 net loss reached $41.5M, driven by $45M in SG&A. Without a significant acceleration in revenue generation, the cash position will deplete quickly as commercialization expenses remain elevated.
A 19% sequential growth in prescriptions translated to only a 7% increase in product revenue, indicating potential headwinds from gross-to-net adjustments or prolonged sampling practices.
⚖️ Verdict: ⚪
Neutral. Foundational metrics like prescriber adoption and script volume are moving in the right direction, but the staggering cost of customer acquisition casts a shadow over the near-term path to profitability.
Key Themes
Revenue Yield Contradicts Prescription Momentum
Management celebrated a 19% sequential increase in paid prescriptions (from ~21,000 in 25Q4 to 25,000 in 26Q1). However, net product revenue grew by only 7% (from $1.59M to $1.7M) over the same period. This discrepancy implies a lower revenue yield per prescription, potentially driven by higher gross-to-net adjustments, continued heavy sampling, or friction in the e-pharmacy channel. This data point contradicts the narrative of a seamlessly scaling commercial launch and requires monitoring.
Direct-to-Consumer (DTC) Activation
The 'Tired of Reading Glasses' DTC campaign featuring Sarah Jessica Parker launched in January 2026 and is demonstrating strong initial engagement. The company reported VIZZ.com website traffic increased up to 10x following national media activations. To further capitalize on this, LENZ initiated a pilot expansion into network and cable television in select markets in April 2026, aiming to bridge the gap between digital consumer awareness and physical ECP visits.
Sales Force and Direct Distribution Expansion
LENZ is aggressively scaling its field presence, expanding its sales force from 88 to 117 territories to increase ECP reach and call frequency. Furthermore, the company launched an ECP direct sales initiative in April 2026, allowing physicians to sell and dispense VIZZ directly from their offices. This bypasses traditional pharmacy bottlenecks, reduces fulfillment time, and could significantly boost conversion rates.
Technology Innovation: Pupil-Selective Miotic
VIZZ (aceclidine 1.44%) represents a major technological leap in ophthalmology as a predominantly pupil-selective miotic. Unlike earlier entrants that caused excessive ciliary muscle stimulation—leading to headaches and poor distance vision—VIZZ specifically targets the iris sphincter muscle to create a pinhole effect. This innovation improves near vision for up to 10 hours and is the scientific foundation driving ECP confidence and the initial 'wow effect' during patient sampling.
Global Commercialization Momentum
International partnerships are accelerating, providing non-dilutive capital and future revenue streams. In Q1 2026, LENZ secured an exclusive distribution agreement with Lunatus for the Middle East, generating $0.2M upfront. Additionally, Marketing Authorization Applications were submitted to the EMA (March) and the UK's MHRA (April), marking the fifth and sixth ex-U.S. regulatory filings.
Opaque Sample-to-Script Conversion
The company's core strategy relies on extensive sampling to drive patient self-selection. While 46,000 total paid prescriptions have been filled since launch, the exact conversion rate from free sample to recurring paid prescription remains opaque. Management has historically declined to provide hard metrics on refill dynamics, making it difficult to quantify the long-term stickiness of the product.
Macro Sensitivity of a Cash-Pay Product
As a 100% cash-pay product, VIZZ is highly exposed to consumer discretionary spending habits. While management has previously argued that quality-of-life products are insulated from economic downturns, a challenging macro environment with sustained inflation could hinder patient willingness to adopt or consistently refill a continuous out-of-pocket expense.
Other KPIs
Decelerating profitability. Net loss widened substantially from $14.6M in 25Q1 and $35.9M in 25Q4. This was driven by the complete shift from R&D (which dropped to zero following approval) to SG&A ($45M) for commercial launch activities. The cash burn trajectory clearly highlights the front-loaded costs of building the presbyopia category.
Down from $292.3M at the end of 2025. The ~$34M quarterly reduction aligns with the high commercial spend. The company maintains that this balance is sufficient to fund operations to post-launch positive cash flow, though execution risk remains elevated.
Guidance
Accelerating. Up from the original 88 territories deployed at launch, the company expects the expanded sales force to be fully deployed by the end of Q2 2026. This aims to increase the frequency and reach of ECP engagement.
Stable. Management reiterated that the current cash balance is anticipated to fund operations until the company reaches post-launch positive cash flow, implying a runway extending well into 2027 based on current burn rates.
Key Questions
Revenue Yield Dynamics
Given the 19% sequential growth in paid prescriptions but only a ~7% increase in net product revenue, what are the current gross-to-net dynamics, and is the April ECP direct sales initiative expected to improve the revenue yield per prescription?
DTC Campaign Conversion
With the DTC campaign launching in January, what specific leading indicators are you tracking to ensure that the 10x spike in web traffic is effectively translating into physical ECP visits and prescriptions?
Prescriber Cohort Stickiness
Are you seeing a meaningful difference in refill rates and prescription volume among the first cohort of prescribers onboarded in October 2025 compared to the newer ECPs acquired in Q1 2026?